TABLE A2.
Subsequent Anticancer Therapies
| Subsequent Therapy | Lenvatinib + Pembrolizumab (n = 241) | Standard of Care (n = 239) |
|---|---|---|
| Patients who received subsequent anticancer therapy, No. (%) | 111 (46.1) | 142 (59.4) |
| Chemotherapy, No. (%) | 98 (40.7) | 116 (48.5) |
| Fluoropyrimidine ± targeted therapy | 18 (7.5) | 25 (10.5) |
| FOLFIRI ± targeted therapy | 15 (6.2) | 33 (13.8) |
| FOLFOX ± targeted therapy | 33 (13.7) | 33 (13.8) |
| FOLFOXIRI ± targeted therapy | 3 (1.2) | 7 (2.9) |
| Irinotecan ± targeted therapy | 2 (0.8) | 8 (3.3) |
| Trifluridine/tipiracil | 31 (12.9) | 26 (10.9) |
| Trifluridine/tipiracil + bevacizumab | 25 (10.4) | 14 (5.9) |
| Targeted therapy, No. (%) | 24 (10.0) | 37 (15.5) |
| Anti–PD-1/PD-L1 | 4 (1.7) | 18 (7.5) |
| Regorafenib | 18 (7.5) | 20 (8.4) |
| Other TKI | 2 (0.8) | 2 (0.8) |
| Other, No. (%) | 10 (4.1) | 26 (10.9) |
Abbreviations: FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; FOLFOXIRI, leucovorin, fluorouracil, oxaliplatin, and irinotecan; TKI, tyrosine kinase inhibitors.